Sobi publishes 2016 Annual Report
Swedish Orphan Biovitrum AB (publ) (Sobi™) publishes today its 2016 Annual Report. The report summarises the business as well as financial highlights for 2016, and gives a deeper insight into the company’s strategic agenda and its patient-centric innovation model.
“We took a major step in 2016 by launching Elocta and Alprolix, two first in class extended half-life Fc fusion clotting factors to people with haemophilia in Europe and in parts of the Middle East. Throughout the year we have come to understand the positive impact that these therapies can bring to patients and physicians, and as these therapies find their place in this important field they will also set the foundation for a period of significant growth for Sobi,” said Geoffrey McDonough, CEO and President, in his statement.
The 2016 Annual Report is available both in print and as an interactive online version, in responsive design to enable viewing on all mobile devices. The online version includes pdf downloads of the report and excel spreadsheets of the financial results, as well as a video comment from CEO Geoffrey McDonough.
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016 Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.
|For more information please contact|
|Media relations||Investor relations|
|Linda Holmström, Senior Communications Manager||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: + 46 708 73 40 95, + 46 8 697 31 74||T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135|
This information is information that Swedish Orphan Biovitrum AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 10:00 am CET on 12 April 2016.
Swedish Orphan Biovitrum AB
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com